OTCMKTS:OSIR Osiris Therapeutics (OSIR) Stock Price, News & Analysis $18.99 0.00 (0.00%) As of 04/17/2019 Add Compare Share Share Stock Analysis Stock Analysis About Osiris Therapeutics Stock (OTCMKTS:OSIR) Get Osiris Therapeutics alerts:Sign Up Key Stats Today's Range$18.99▼$18.9950-Day Range$18.99▼$18.9952-Week Range$7.01▼$19.30VolumeN/AAverage Volume205,753 shsMarket Capitalization$655.69 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Osiris Therapeutics, Inc. was a biotechnology company focused on developing and commercializing regenerative medicine products derived from human tissues. Its offerings were designed to support wound healing, tissue repair and orthopedic applications. The company’s principal products included Grafix, a cryopreserved placental membrane used in wound care; Stravix, a placental tissue product used in surgical and regenerative procedures; and Cartiform, a viable osteochondral allograft intended for cartilage repair. Osiris marketed its products primarily through the U.S. health care system. In 2019, Smith+Nephew acquired Osiris Therapeutics, integrating its regenerative medicine portfolio into Smith+Nephew’s Advanced Wound Management and orthopedic businesses. As a result, Osiris no longer operates as an independent publicly traded company.AI Generated. May Contain Errors. Read More Receive OSIR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Osiris Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OSIR Stock News HeadlinesOsiris Chairman responds to columnDecember 24, 2025 | marketwatch.comRyoncil, the first FDA-approved mesenchymal stromal cell therapyMarch 3, 2025 | finance.yahoo.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.October 5 at 1:00 AM | Chaikin Analytics (Ad)Global Topical Wound Agents Market Size To Exceed USD 3.7 Billion By 2033 | CAGR Of 6.89%May 25, 2024 | finance.yahoo.comTissue Engineering Market Set to Soar Past USD 32.45 Billion by 2030February 2, 2024 | finance.yahoo.comAnti-biofilm Wound Dressing Market Size & Share to Surpass US$ 2.3 Billion by 2030 - Exclusive Report by Persistence Market ResearchJanuary 19, 2024 | finance.yahoo.comNASA launches mission to intercept ‘God of Chaos’ asteroid as it nears Earth’s orbitDecember 28, 2023 | nypost.comNImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023December 11, 2023 | markets.businessinsider.comSee More Headlines OSIR Stock Analysis - Frequently Asked Questions How have OSIR shares performed this year? Osiris Therapeutics' stock was trading at $18.99 at the beginning of the year. Since then, OSIR shares have increased by 0.0% and is now trading at $18.99. How do I buy shares of Osiris Therapeutics? Shares of OSIR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Osiris Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Osiris Therapeutics investors own include MiMedx Group (MDXG), Bristol Myers Squibb (BMY), Ionis Pharmaceuticals (IONS) and Mesoblast (MESO). Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:OSIR Previous SymbolNASDAQ:OSIR CIK1360886 Webwww.osiris.com Phone443-545-1800FaxN/AEmployees342Year Founded1992Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares34,528,000Free FloatN/AMarket Cap$655.69 million OptionableNot Optionable BetaN/A Social Links The 10 Best High-Yield Dividend Stocks for 2026Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (OTCMKTS:OSIR) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Osiris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Osiris Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
